{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:22:50Z","timestamp":1793085770004,"version":"4.5.0"},"reference-count":112,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81660365, 81601912"],"award-info":[{"award-number":["81660365, 81601912"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2017.00234","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T23:13:25Z","timestamp":1513725205000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":136,"title":["Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review"],"prefix":"10.3389","volume":"4","author":[{"given":"Haidi","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2741\/4301","article-title":"The expression and function of microRNAs in bone homeostasis","volume":"20","author":"Pi","year":"2015","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00223-001-1079-x","article-title":"A role for cell-surface CSF-1 in osteoblast-mediated osteoclastogenesis","volume":"70","author":"Yao","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/15476286.2014.996462","article-title":"The role of microRNAs in osteoclasts and osteoporosis","volume":"11","author":"Tang","year":"2014","journal-title":"RNA Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mad.2015.02.001","article-title":"Osteoporosis: from osteoscience to neuroscience and beyond","author":"Kwan","year":"2015","journal-title":"Mech Ageing Dev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/jor.20190","article-title":"Implant wear induces inflammation, but not osteoclastic bone resorption, in RANK(-\/-) mice","volume":"24","author":"Ren","year":"2006","journal-title":"J Orthop Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/01.blo.0000238813.95035.1b","article-title":"The cellular and molecular biology of periprosthetic osteolysis","volume":"454","author":"Purdue","year":"2007","journal-title":"Clin Orthop Relat Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8046","DOI":"10.1016\/j.actbio.2013.05.005","article-title":"Osteolysis around total knee arthroplasty: a review of pathogenetic mechanisms","volume":"9","author":"Gallo","year":"2013","journal-title":"Acta Biomater"},{"key":"B13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/1529-0131(200004)43:4<821::AID-ANR12>3.0.CO;2-T","article-title":"Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis","volume":"43","author":"Romas","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","first-page":"263625","DOI":"10.1155\/2014\/263625","article-title":"Cytokine-mediated bone destruction in rheumatoid arthritis","volume":"2014","author":"Jung","year":"2014","journal-title":"J Immunol Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10555-013-9488-7","article-title":"RANK-mediated signaling network and cancer metastasis","volume":"33","author":"Chu","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1159\/000371845","article-title":"The RANKL-RANK story","volume":"16","author":"Nagy","year":"2015","journal-title":"Gerontology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1172\/JCI8489","article-title":"Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype","volume":"105","author":"Kurihara","year":"2000","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"The lancet Diabetes & endocrinology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17843286.2017.1348001","article-title":"Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab","author":"Loyson","year":"2017","journal-title":"Acta Clin Belg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1172\/JCI27071","article-title":"Pathogenesis of osteoporosis: concepts, conflicts, and prospects","volume":"115","author":"Raisz","year":"2005","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40199-017-0167-z","article-title":"New horizons in treatment of osteoporosis","volume":"25","author":"Tabatabaei-Malazy","year":"2017","journal-title":"Daru"},{"key":"B24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1242\/jcs.063032","article-title":"Bone remodelling at a glance","volume":"124","author":"Crockett","year":"2011","journal-title":"J Cell Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/bonekey.2012.59","article-title":"Osteoimmunology: the expanding role of immunoreceptors in osteoclasts and bone remodeling","volume":"1","author":"Long","year":"2012","journal-title":"Bonekey Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.tem.2012.05.005","article-title":"New insights into osteoclastogenic signaling mechanisms","volume":"23","author":"Nakashima","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jbmr.1547","article-title":"Osteocyte RANKL: new insights into the control of bone remodeling","volume":"27","author":"Xiong","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11914-007-0024-y","article-title":"The RANKL\/RANK\/OPG pathway","volume":"5","author":"Boyce","year":"2007","journal-title":"Curr Osteoporos Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.3892\/mmr.2015.3152","article-title":"Receptor activator of nuclear factor-kappaB ligand (RANKL)\/RANK\/osteoprotegerin system in bone and other tissues (Review)","volume":"11","author":"Liu","year":"2015","journal-title":"Mol Med Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/00003086-200112000-00007","article-title":"Wear and periprosthetic osteolysis: the problem","volume":"393","author":"Harris","year":"2001","journal-title":"Clin Orthop Relat Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.arth.2003.09.001","article-title":"Long-term follow-up care recommendations after total hip and knee arthroplasty: results of the American Association of Hip and Knee Surgeons\u2019 member survey","volume":"18","author":"Teeny","year":"2003","journal-title":"J Arthroplasty"},{"key":"B32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0002-9440(10)65266-2","article-title":"Tumor necrosis factor-alpha mediates orthopedic implant osteolysis","volume":"154","author":"Merkel","year":"1999","journal-title":"Am J Pathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1016\/j.biomaterials.2004.01.053","article-title":"The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts","volume":"25","author":"Pioletti","year":"2004","journal-title":"Biomaterials"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5212","DOI":"10.1016\/j.biomaterials.2006.05.054","article-title":"The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants","volume":"27","author":"Holding","year":"2006","journal-title":"Biomaterials"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2013.09.034","article-title":"Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-kappaB as a therapeutic target","volume":"10","author":"Lin","year":"2014","journal-title":"Acta Biomater"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#","article-title":"Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients","volume":"44","author":"Kotake","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/cncr.21978","article-title":"Expression of RANKL\/RANK\/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation","volume":"107","author":"Chen","year":"2006","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/1078-0432.CCR-10-2507","article-title":"Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL\/RANK\/OPG pathway in tumorigenesis and metastasis","volume":"18","author":"Dougall","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e58361","DOI":"10.1371\/journal.pone.0058361","article-title":"Differential expression of the RANKL\/RANK\/OPG system is associated with bone metastasis in human non-small cell lung cancer","volume":"8","author":"Peng","year":"2013","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1615\/CritRevEukarGeneExpr.v19.i1.30","article-title":"Action of RANKL and OPG for osteoclastogenesis","volume":"19","author":"Kobayashi","year":"2009","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"B41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1517\/14728222.2010.511179","article-title":"Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis","volume":"14","author":"Jules","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1359\/jbmr.2003.18.6.1088","article-title":"RANKL expression is related to the differentiation state of human osteoblasts","volume":"18","author":"Atkins","year":"2003","journal-title":"J Bone Miner Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1359\/jbmr.060604","article-title":"RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone","volume":"21","author":"Atkins","year":"2006","journal-title":"J Bone Miner Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1182\/blood-2002-01-0148","article-title":"Immunocytochemistry reveals RANKL expression of myeloma cells","volume":"99","author":"Sezer","year":"2002","journal-title":"Blood"},{"key":"B45","first-page":"39","article-title":"On a form of chronic inflammation of bones (osteitis deformans)","volume":"60","author":"Paget","year":"1877","journal-title":"Med Chir Trans"},{"key":"B46","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S8756-3282(02)00817-7","article-title":"Guidelines on the management of Paget\u2019s disease of bone","volume":"31","author":"Selby","year":"2002","journal-title":"Bone"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1172\/JCI9133","article-title":"Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget\u2019s disease of bone","volume":"105","author":"Menaa","year":"2000","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/path.1953","article-title":"Bone stromal cells in pagetic bone and Paget\u2019s sarcoma express RANKL and support human osteoclast formation","volume":"209","author":"Sun","year":"2006","journal-title":"J Pathol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"39S","DOI":"10.1016\/S8756-3282(99)00045-9","article-title":"Mechanisms of abnormal bone turnover in Paget\u2019s disease","volume":"24","author":"Roodman","year":"1999","journal-title":"Bone"},{"key":"B50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1172\/JCI24281","article-title":"Paget disease of bone","volume":"115","author":"Roodman","year":"2005","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.2106\/JBJS.N.00075","article-title":"Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry","volume":"96","author":"Hagen","year":"2014","journal-title":"J Bone Joint Surg Am"},{"key":"B52","first-page":"147","article-title":"Nitrogen containing bisphosphonates associated osteonecrosis of the jaws: a review for past 10 year literature","volume":"11","author":"Kumar","year":"2014","journal-title":"Dent Res J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1517\/14740338.2014.951329","article-title":"Bisphosphonate-related osteonecrosis of the jaw: an Italian post-marketing surveillance analysis","volume":"13","author":"Parretta","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"B54","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0889-8529(02)00079-8","article-title":"Bisphosphonates","volume":"32","author":"McClung","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0022034513501876","article-title":"Bis-enoxacin inhibits bone resorption and orthodontic tooth movement","volume":"92","author":"Toro","year":"2013","journal-title":"J Dent Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e92119","DOI":"10.1371\/journal.pone.0092119","article-title":"Bis-enoxacin blocks rat alveolar bone resorption from experimental periodontitis","volume":"9","author":"Rivera","year":"2014","journal-title":"PLoS One"},{"key":"B58","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3389\/fphar.2017.00355","article-title":"The beneficial effects of bisphosphonate-enoxacin on cortical bone mass and strength in ovariectomized rats","volume":"8","author":"Liu","year":"2017","journal-title":"Front Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.it.2012.08.006","article-title":"Colony stimulating factors and myeloid cell biology in health and disease","volume":"34","author":"Hamilton","year":"2013","journal-title":"Trends Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1046\/j.1365-2249.2000.01125.x","article-title":"Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF: evidence of macrophage infiltration and local proliferation","volume":"119","author":"Bischof","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"B62","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1189\/jlb.68.1.144","article-title":"The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF","volume":"68","author":"Campbell","year":"2000","journal-title":"J Leukoc Biol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1186\/ar2940","article-title":"c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis","volume":"12","author":"Paniagua","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13075-016-0973-6","article-title":"Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis","volume":"18","author":"Garcia","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1172\/JCI8672","article-title":"M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss","volume":"105","author":"Cenci","year":"2000","journal-title":"J Clin Invest"},{"key":"B66","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1189\/jlb.0310158","article-title":"CSF-1, IGF-1, and the control of postnatal growth and development","volume":"88","author":"Gow","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"15482","DOI":"10.18632\/oncotarget.3855","article-title":"Anti-CSF-1 treatment is effective to prevent carcinoma invasion induced by monocyte-derived cells but scarcely by microglia","volume":"6","author":"Rietkotter","year":"2015","journal-title":"Oncotarget"},{"key":"B68","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1126\/science.1154370","article-title":"Discovery of a cytokine and its receptor by functional screening of the extracellular proteome","volume":"320","author":"Lin","year":"2008","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.str.2012.02.010","article-title":"Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R","volume":"20","author":"Ma","year":"2012","journal-title":"Structure"},{"key":"B70","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.str.2013.01.018","article-title":"Human IL-34 and CSF-1 establish structurally similar extracellular assemblies with their common hematopoietic receptor","volume":"21","author":"Felix","year":"2013","journal-title":"Structure"},{"key":"B71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/path.2684","article-title":"Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis","volume":"221","author":"Baud\u2019huin","year":"2010","journal-title":"J Pathol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e18689","DOI":"10.1371\/journal.pone.0018689","article-title":"The critical role of IL-34 in osteoclastogenesis","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"key":"B73","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/cbin.10771","article-title":"AG490 suppresses interleukin-34-mediated osteoclastogenesis in mice bone marrow macrophages","volume":"41","author":"Cheng","year":"2017","journal-title":"Cell Biol Int"},{"key":"B74","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"B75","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"B76","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"B77","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"key":"B79","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1074\/jbc.M400524200","article-title":"Sclerostin inhibition of Wnt-3a-induced C3H10T1\/2 cell differentiation is indirect and mediated by bone morphogenetic proteins","volume":"280","author":"Winkler","year":"2005","journal-title":"J Biol Chem"},{"key":"B81","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1759720X13510479","article-title":"Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases","volume":"6","author":"Lewiecki","year":"2014","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.2489","article-title":"The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/jbmr.3176","article-title":"Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass","volume":"32","author":"Keaveny","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B85","doi-asserted-by":"publisher","first-page":"6217286","DOI":"10.1155\/2016\/6217286","article-title":"Sclerostin antibody therapy for the treatment of osteoporosis: clinical prospects and challenges","volume":"2016","author":"MacNabb","year":"2016","journal-title":"J Osteoporos"},{"key":"B86","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2174\/138161207780162962","article-title":"Emerging roles of cysteine cathepsins in disease and their potential as drug targets","volume":"13","author":"Vasiljeva","year":"2007","journal-title":"Curr Pharm Des"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.jaad.2010.11.033","article-title":"Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib","volume":"66","author":"Runger","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","article-title":"The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K","volume":"18","author":"Gauthier","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"B90","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/clpt.2009.60","article-title":"Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies","volume":"86","author":"Stoch","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1759720X15580903","article-title":"Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women","volume":"7","author":"Chapurlat","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.maturitas.2015.07.003","article-title":"Bone biology, signaling pathways, and therapeutic targets for osteoporosis","volume":"82","author":"Iniguez-Ariza","year":"2015","journal-title":"Maturitas"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1007\/s11033-010-0004-7","article-title":"The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis","volume":"37","author":"Yuan","year":"2010","journal-title":"Mol Biol Rep"},{"key":"B94","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nrm2272","article-title":"Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology","volume":"8","author":"Forgac","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1021\/bi100397s","article-title":"Regulation and isoform function of the V-ATPases","volume":"49","author":"Toei","year":"2010","journal-title":"Biochemistry"},{"key":"B96","doi-asserted-by":"crossref","first-page":"24102","DOI":"10.1016\/S0021-9258(19)51053-5","article-title":"A novel accessory subunit for vacuolar H(+)-ATPase from chromaffin granules","volume":"269","author":"Supek","year":"1994","journal-title":"J Biol Chem"},{"key":"B97","doi-asserted-by":"publisher","first-page":"10939","DOI":"10.1074\/jbc.273.18.10939","article-title":"Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules","volume":"273","author":"Ludwig","year":"1998","journal-title":"J Biol Chem"},{"key":"B98","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00424-007-0382-4","article-title":"V-ATPase functions in normal and disease processes","volume":"457","author":"Hinton","year":"2009","journal-title":"Pflugers Arch"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1074\/jbc.M109756200","article-title":"Mutations in subunit C of the vacuolar ATPase confer resistance to bafilomycin and identify a conserved antibiotic binding site","volume":"277","author":"Bowman","year":"2002","journal-title":"J Biol Chem"},{"key":"B100","doi-asserted-by":"publisher","first-page":"40544","DOI":"10.1074\/jbc.M207345200","article-title":"Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c","volume":"277","author":"Huss","year":"2002","journal-title":"J Biol Chem"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1359\/jbmr.070613","article-title":"Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption","volume":"22","author":"Sorensen","year":"2007","journal-title":"J Bone Miner Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"17894","DOI":"10.1074\/jbc.M111.280511","article-title":"Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis","volume":"287","author":"Toro","year":"2012","journal-title":"J Biol Chem"},{"key":"B103","doi-asserted-by":"publisher","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B104","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.bone.2006.09.025","article-title":"Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women","volume":"40","author":"Henriksen","year":"2007","journal-title":"Bone"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1359\/jbmr.2003.18.12.2180","article-title":"Role of gastrointestinal hormones in postprandial reduction of bone resorption","volume":"18","author":"Henriksen","year":"2003","journal-title":"J Bone Miner Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10354-015-0344-y","article-title":"Anti-TNF in rheumatoid arthritis: an overview","volume":"165","author":"Radner","year":"2015","journal-title":"Wien Med Wochenschr"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1359\/jbmr.2000.15.8.1459","article-title":"Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation","volume":"15","author":"Quinn","year":"2000","journal-title":"J Bone Miner Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.4049\/jimmunol.173.8.4838","article-title":"Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo","volume":"173","author":"Kitaura","year":"2004","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1172\/JCI26132","article-title":"M-CSF mediates TNF-induced inflammatory osteolysis","volume":"115","author":"Kitaura","year":"2005","journal-title":"J Clin Invest"},{"key":"B111","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/00004650-200509000-00004","article-title":"New rheumatoid arthritis treatments","volume":"19","author":"Bruce","year":"2005","journal-title":"Holist Nurs Pract"},{"key":"B112","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1586\/1744666X.4.2.157","article-title":"Adalimumab for early rheumatoid arthritis","volume":"4","author":"Bykerk","year":"2008","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2017.00234\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T22:14:07Z","timestamp":1693347247000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2017.00234\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":112,"alternative-id":["10.3389\/fmed.2017.00234"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2017.00234","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,20]]},"article-number":"234"}}